Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CTSB | P07858 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151699 | 0.85 | CTSB (0.46) | CHRM1MEN1KMT2ACTSBCTSS | |
| SCHEMBL9951765 | 0.81 | CTSS (0.46) | CTSBCTSSCTSLRAB9ACTSK | |
| SCHEMBL2823474 | 0.80 | CTSB (0.46) | CHRM1MEN1KMT2ACTSBCTSS | |
| SCHEMBL9952383 | 0.79 | CTSB (0.44) | CTSBCTSSCTSLRAB9ACTSK | |
| SCHEMBL2826325 | 0.76 | CTSL (0.46) | CTSBCTSSCTSLRAB9A | |
| SCHEMBL1305698 | 0.73 | CHRM1 (0.50) | CHRM1MEN1KMT2ACTSBCTSS | |
| SCHEMBL9951842 | 0.73 | CTSS (0.44) | CTSBCTSSCTSLRAB9ACTSK | |
| SCHEMBL18038887 | 0.71 | CTSL (0.46) | MEN1KMT2ACTSBCTSSCTSL | |
| SCHEMBL1567508 | 0.71 | NPSR1 (0.38) | CHRM1MEN1KMT2A | |
| SCHEMBL17141146 | 0.71 | CTSL (0.51) | CTSBCTSSCTSLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | H. LUNDBECK A/S (DK) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | SLC10A1, CLIC1, ABCB11 | CHRM1 576/4885MEN1 1887/4885KMT2A 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.